December 1, 2003
Boston Cure Project
An earlier posting described promising results in a secondary progressive MS trial of combination interferon beta and azathioprine therapy. Another team has now studied the efficacy of this combination in relapsing-remitting MS. The 23 subjects were either previously untreated or had been unresponsive to courses of IFN-b or AZA alone. The combination therapy appeared to reduce relapse rate, disability progression, and MRI lesion counts. However, this study had certain limitations such as small size and lack of a control arm, so it provides only general encouragement rather than a strong demonstration of efficacy.
Copyright © 2003, Boston Cure Project